Finding relief in the aftermath of Hurricane Maria: A patient’s journey from Puerto Rico to the National Institutes of Health

Jesus Garces-Soto and his wife, Lyssette Santiago, never expected to travel from Puerto Rico to the National Institutes of Health (NIH) in Bethesda, Maryland. On the same day that Hurricane Maria, a storm with 150-mile-per-hour winds, made direct landfall on Puerto Rico in 2017, Garces-Soto needed to seek treatment for an infection related to bladder cancer. Destruction from the hurricane took out the hospital’s electricity, and with no generator, it was difficult to provide adequate care. With help from members of the American Cancer Society and the National Cancer Institute, Garces-Soto and Santiago were flown to NIH where Garces-Soto is receiving care from Andrea Apolo, M.D., Investigator and Lasker Clinical Research Scholar in the Genitourinary Malignancies Branch. Read more...

Pancreatic cancer cells

New clinical trial explores precision treatment for advanced pancreatic cancer

Posted: Nov 7, 2017

A new phase II clinical trial to assess the safety and efficacy of a drug called selumetinib for treating patients with advanced pancreatic cancer whose tumors harbor a specific genetic marker has opened at the Center for Cancer Research and is currently recruiting participants. Read more...

New clinical trial explores precision treatment for advanced pancreatic cancer
Lymphoma cells

New clinical trial explores targeted therapy for three types of rare and aggressive lymphoma

Posted: Nov 3, 2017

Gray-zone lymphoma, central nervous system lymphoma and extra-nodal diffuse large B-cell lymphomas are often resistant to treatment with radiation and standard chemotherapy. Mark Roschewski, M.D., of the Lymphoid Malignancies Branch, is leading a study to determine if pembrolizumab can improve outcomes for patients with certain rare lymphomas. Read more... 

New clinical trial explores targeted therapy for three types of rare and aggressive lymphoma
Lung cancer cells

November is Lung Cancer Awareness Month

Posted: Nov 1, 2017

To recognize Lung Cancer Awareness Month this November, we are highlighting our investigators who are making discoveries in this important research area.  Read more...

November is Lung Cancer Awareness Month
Lung cancer cells

Combination therapy for advanced or metastatic non-small cell lung cancer will be tested in new clinical trial

Posted: Nov 1, 2017

Non-small cell lung cancer (NSCLC) develops when abnormal lung cells begin to grow out of control. These cells can form into a tumor and spread to other areas of the body. David Schrump, M.D., of the Thoracic and Gastrointestinal Oncology Branch is leading a clinical trial of a new combination treatment for patients with advanced or metastatic NSCLC that cannot be treated surgically. Read more... 

Combination therapy for advanced or metastatic non-small cell lung cancer will be tested in new clinical trial
Pepe Bryan

CCR clinical trial opens new door for pediatric cancer patient

Posted: Oct 30, 2017

When standard treatment for adult T-cell leukemia/lymphoma (ATLL) proved ineffective, Pepe Bryan and his family traveled from their home in Kingston, Jamaica, to participate in a clinical trial at the NIH Clinical Center led by Kevin Conlon, M.D., of the Lymphoid Malignancies Branch. ATLL is a rare and aggressive type of blood cancer that affects the immune system’s T cells. While receiving treatment at the Clinical Center, Pepe stayed at the Children’s Inn — a temporary residence on the NIH campus for families with children participating in clinical trials. As Pepe’s fight against cancer continues, his demeanor remains positive and hopeful. “The NIH means life to me. And The Children’s Inn is a great place. Let me tell you, it’s wonderful. They give you food and housing, and they take you on outings and activities. It’s wonderful!” Read more about Pepe's story…

CCR clinical trial opens new door for pediatric cancer patient
human brain with metastases of breast cancer

New clinical trial aims to prevent breast cancer from recurring in the brain

Posted: Oct 27, 2017

In some types of breast cancer, the tumor cells spread more frequently to the brain. A new clinical trial run by CCR investigators will test whether a drug called temozolomide can prevent these deadly lesions from recurring. Read more... 

New clinical trial aims to prevent breast cancer from recurring in the brain

CCR research lays foundation for FDA approval of CAR T cell therapy Yescarta

Posted: Oct 26, 2017

Decades ago, the use of chimeric antigen receptor (CAR)-expressing T cells as an effective form of immunotherapy was a speculative idea. In 2010, a breakthrough clinical trial conducted by Steven Rosenberg, M.D., Ph.D., and his clinical team showed that CAR T cells recognizing the CD19 receptor were useful in the treatment of some types of B-cell malignancies. Read more...

CCR research lays foundation for FDA approval of CAR T cell therapy Yescarta

Researchers discover promising new targets for treatment of fatty liver disease

Posted: Oct 19, 2017

Researchers have identified potential new drug targets for the prevention and treatment of non-alcoholic fatty liver disease (NAFLD). The new study, which was a collaborative effort between scientists in the Laboratory of Metabolism at CCR and Peking University, was published October 9, 2017, in Nature Medicine. Read more…

Researchers discover promising new targets for treatment of fatty liver disease

Shiv Grewal receives 2017 Indian National Science Academy Foreign Fellowship

Posted: Oct 17, 2017

Shiv Grewal, Ph.D., Chief of the Laboratory of Biochemistry and Molecular Biology, has been named an Indian National Science Academy (INSA) Foreign Fellow for his pioneering contributions on the role of epigenetic modifications in heterochromatin assembly and discovery of relation between heterochromatin assembly and RNAi. The INSA Foreign Fellowship is designated to scientists recognized as international leaders in their field. Dr. Grewal is one of four researchers to receive the 2017 fellowship.

Shiv Grewal receives 2017 Indian National Science Academy Foreign Fellowship

Former CCR fellow named a 2017 STAT Wunderkind

Posted: Oct 17, 2017

Daniel Webster, Ph.D., a former fellow at CCR, has been named a 2017 STAT Wunderkind for the development of “Mole Mapper” — an app that catalogs potentially cancerous moles and helps those at risk of skin cancer effectively communicate with researchers and clinicians. STAT News, a publication produced by Boston Globe Media, annually selects 26 young scientists as “wunderkinds” in recognition of their efforts to answer some of the biggest questions in medicine. According to STAT, “Over the past several months, a team of STAT editors and reporters pored through nearly 300 nominations from across North America. We didn’t set an age limit; we were on the hunt for the most impressive doctors and researchers on the cusp of launching their careers but not yet fully independent. Most were postdocs, fellows, and biopharma employees working with more senior scientists.” Dr. Webster currently works at Sage Bionetworks. 

Former CCR fellow named a 2017 STAT Wunderkind

Pages